Evidence map›Paper›PMID 39973250›Full record

ArticleHuman vaccines & immunotherapeutics2025

Stability study of recombinant 9-valent human papillomavirus vaccine based on

Yuying Liu, Dan Chen, Li Zhao, Haijiang Zhang, Shuming Wu, Xiao Chen, Ercui Shen, Ling Li, Zengmin Yang, Yan Wang and 17 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Immunogenicity of anVaccines · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Yuying LiuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.ORCID 0000-0003-0415-1124
Dan ChenR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Li ZhaoR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Haijiang ZhangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Shuming WuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Xiao ChenR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Ercui ShenR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Ling LiR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Zengmin YangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Yan WangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Fei YinR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Yao ZhangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Yazheng ShiR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Shuyi ZhouR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Shuang LiR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Xiaoli DuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Jiaping GuoR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Di WangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Huan WangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Shujuan LiuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Guiying JinR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Hongcai ZhangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Xinyu YuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Xuejiao ChenR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Lulu ShangR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Yang LiuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.
Yongjiang LiuR&D Center, Beijing Health Guard Biotechnology Inc., BDA, Beijing, China.ORCID 0009-0007-2437-6992

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study reports on the long-term stability of a recombinant 9-valent HPV vaccine, addressing a gap in the literature as previous research did not extend beyond 72 months. The vaccine targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 and was produced using an

Indexed as

Escherichia coliPapillomavirus VaccinesAnimalsCapsid ProteinsDrug StabilityFemaleHumansHydrogen-Ion ConcentrationLightMiceOncogene Proteins, ViralPapillomavirus InfectionsTemperatureVaccine PotencyVaccines, SyntheticVaccines, Virus-Like ParticleCapsid ProteinsHPV L1 protein, Human papillomavirusOncogene Proteins, ViralPapillomavirus VaccinesVaccines, SyntheticVaccines, Virus-Like ParticleEscherichia colirecombinant 9-valent human papillomavirus vaccinevaccine stability

Identifiers

PMID39973250
PMCPMC11845052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.